Mereo BioPharma Group (MREO) Competitors

Mereo BioPharma Group (NASDAQ:MREO) and Indivior (NASDAQ:INDV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Do analysts prefer MREO or INDV?

Mereo BioPharma Group presently has a consensus target price of $7.71, suggesting a potential upside of 242.10%. Indivior has a consensus target price of $15.00, suggesting a potential upside of 33.16%. Given Mereo BioPharma Group's higher probable upside, research analysts plainly believe Mereo BioPharma Group is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Indivior	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Is MREO or INDV more profitable?

Mereo BioPharma Group has a net margin of 0.00% compared to Indivior's net margin of -3.96%. Mereo BioPharma Group's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	N/A	N/A
Indivior	-3.96%	-241.73%	15.09%

Do institutionals & insiders hold more shares of MREO or INDV?

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 5.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor MREO or INDV?

Mereo BioPharma Group received 43 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 80.60% of users gave Mereo BioPharma Group an outperform vote.

Company	Underperform	Outperform
Mereo BioPharma Group	Outperform Votes 54 80.60%	Underperform Votes 13 19.40%
Indivior	Outperform Votes 11 100.00%	Underperform Votes No Votes

Which has preferable earnings & valuation, MREO or INDV?

Indivior has higher revenue and earnings than Mereo BioPharma Group. Indivior is trading at a lower price-to-earnings ratio than Mereo BioPharma Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$1M	358.55	-$29.47M	-$0.07	-32.21
Indivior	$1.17B	1.33	$2M	-$0.31	-36.34

Does the media refer more to MREO or INDV?

In the previous week, Mereo BioPharma Group had 11 more articles in the media than Indivior. MarketBeat recorded 14 mentions for Mereo BioPharma Group and 3 mentions for Indivior. Indivior's average media sentiment score of 1.68 beat Mereo BioPharma Group's score of -0.01 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mereo BioPharma Group	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Indivior	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk and volatility, MREO or INDV?

Mereo BioPharma Group has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Summary

Mereo BioPharma Group beats Indivior on 11 of the 18 factors compared between the two stocks.